Literature DB >> 17600697

Membrane type matrix metalloproteinases (MMPs) show differential expression in non-small cell lung cancer (NSCLC) compared to normal lung: correlation of MMP-14 mRNA expression and proteolytic activity.

J M Atkinson1, C J Pennington, S W Martin, V A Anikin, A J Mearns, P M Loadman, D R Edwards, J H Gill.   

Abstract

Improved understanding of the involvement of matrix metalloproteinases (MMPs), including membrane-type MMPs (MT-MMPs), in human tumours has potential diagnostic, prognostic and therapeutic implications. We assessed the relationship between MT-MMP expression and clinicopathological parameters in human non-small cell lung cancer (NSCLC) and histologically normal lung tissue by quantitative Real Time PCR (qRT-PCR). All MT-MMPs (MMPs 14-17, 24 and 25) were detected by qRT-PCR with significantly higher MMP-14, -15 and -17 expression observed in tumour relative to normal lung specimens. MMP-16 was undetectable in normal lung but expressed in 8% tumours. MMP-15 demonstrated significant overexpression in adenocarcinomas relative to squamous cell carcinomas and normal lung tissue. MMP-14 mRNA expression strongly correlated to MMP-14 proteolytic activity in preclinical tumour models, indicating that qRT-PCR may predict MMP-14 activity levels in NSCLC. These data suggest that MMP-14, -15 and -17 may be good markers of disease, or therapeutic targets for treatment of human NSCLC.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17600697     DOI: 10.1016/j.ejca.2007.05.009

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  24 in total

Review 1.  Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.

Authors:  Xiao-Xiang Zhang; Henry S Eden; Xiaoyuan Chen
Journal:  J Control Release       Date:  2011-10-26       Impact factor: 9.776

Review 2.  Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression.

Authors:  Kyle J Isaacson; M Martin Jensen; Nithya B Subrahmanyam; Hamidreza Ghandehari
Journal:  J Control Release       Date:  2017-01-31       Impact factor: 9.776

3.  A role of MMP-14 in the regulation of invasiveness of nasopharyngeal carcinoma.

Authors:  Jian Zhao; Zhongyu Kong; Feng Xu; Wei Shen
Journal:  Tumour Biol       Date:  2015-06-04

4.  MMP-14 overexpression correlates with poor prognosis in non-small cell lung cancer.

Authors:  Yu-Zhou Wang; Kun-Peng Wu; Ai-Bing Wu; Zhi-Cheng Yang; Jin-Mei Li; Yan-Li Mo; Meng Xu; Bin Wu; Zhi-Xiong Yang
Journal:  Tumour Biol       Date:  2014-07-02

5.  Decreased MT1-MMP in gastric cancer suppressed cell migration and invasion via regulating MMPs and EMT.

Authors:  Wenfeng Li; Shouzhi Li; Liang Deng; Shibin Yang; Mingzhe Li; Shuo Long; Sile Chen; Fuxiang Lin; Longbin Xiao
Journal:  Tumour Biol       Date:  2015-04-08

Review 6.  Tumour endoproteases: the cutting edge of cancer drug delivery?

Authors:  J M Atkinson; C S Siller; J H Gill
Journal:  Br J Pharmacol       Date:  2008-01-21       Impact factor: 8.739

7.  New Strategies for the Next Generation of Matrix-Metalloproteinase Inhibitors: Selectively Targeting Membrane-Anchored MMPs with Therapeutic Antibodies.

Authors:  Laetitia Devy; Daniel T Dransfield
Journal:  Biochem Res Int       Date:  2010-10-28

8.  MMP-14 can serve as a prognostic marker in patients with supraglottic cancer.

Authors:  Huiyan Zhang; Ming Liu; Yanan Sun; Jianguang Lu
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-13       Impact factor: 2.503

9.  Expression analysis of three miRNAs, miR-26a, miR-29b and miR-519d, in relation to MMP-2 expression level in non-small cell lung cancer patients: a pilot study.

Authors:  D Pastuszak-Lewandoska; J Kordiak; K H Czarnecka; M Migdalska-Sęk; E Nawrot; D Domańska-Senderowska; J M Kiszałkiewicz; A Antczak; P Górski; E Brzeziańska-Lasota
Journal:  Med Oncol       Date:  2016-07-22       Impact factor: 3.064

10.  Insufficient CD100 shedding contributes to suppression of CD8+ T-cell activity in non-small cell lung cancer.

Authors:  Hong-Min Wang; Xiao-Hong Zhang; Li-Qun Ye; Kai Zhang; Ning-Ning Yang; Shen Geng; Jing Chen; Shun-Xin Zhao; Kang-Li Yang; Fei-Fei Fan
Journal:  Immunology       Date:  2020-04-07       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.